Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus MONISTAT DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus MONISTAT DERM.
GRISEOFULVIN, ULTRAMICROSIZE vs MONISTAT-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
Miconazole inhibits fungal lanosterol 14α-demethylase, a cytochrome P450 enzyme, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
Topical: Apply once daily to affected areas for 2-4 weeks. Vaginal: One 200 mg suppository at bedtime for 3 days, or one 100 mg suppository at bedtime for 7 days, or one 1200 mg suppository as a single dose.
None Documented
None Documented
9-24 hours (mean 15 hours); prolonged in liver disease.
Terminal elimination half-life is approximately 24–30 hours, supporting twice-daily or once-daily dosing for dermatologic infections.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Primarily fecal (biliary) elimination as unchanged drug and metabolites; <1% renal excretion of unchanged drug.
Category D/X
Category C
Antifungal
Antifungal